LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (LEVEL)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Sponsor: Medpace, Inc.
Listed as NCT05983250, this PHASE3 trial focuses on Pulmonary Hypertension and remains actively recruiting participants. Sponsored by Medpace, Inc., it has been updated 16 times since 2024, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Apr 2025 [monthly]
Recruiting PHASE3
▶ Show 11 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medpace, Inc.
- Northwestern University
- Tenax Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .